To expand the tropical disease product priority review voucher program to encourage treatments for the Middle East respiratory syndrome.
The bill’s titles are written by its sponsor.
Sep 14, 2016
114th Congress, 2015–2017
Died in a previous Congress
This bill was introduced on September 14, 2016, in a previous session of Congress, but was not enacted.
Representative for California's 52nd congressional district
Read Text »
Last Updated: Sep 14, 2016
Length: 2 pages
This is the first step in the legislative process.
H.R. 6033 (114th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
This bill was introduced in the 114th Congress, which met from Jan 6, 2015 to Jan 3, 2017. Legislation not enacted by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
Civic Impulse. (2017). H.R. 6033 — 114th Congress: Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act. Retrieved from https://www.govtrack.us/congress/bills/114/hr6033
“H.R. 6033 — 114th Congress: Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act.” www.GovTrack.us. 2016. May 29, 2017 <https://www.govtrack.us/congress/bills/114/hr6033>
|title=H.R. 6033 (114th)
|accessdate=May 29, 2017
|author=114th Congress (2016)
|date=September 14, 2016
|quote=Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.